IOVANCE BIOTHERAPEUTICS, INC. Human Resources Contracts & Agreements
41 Contracts & Agreements
- Bonus & Incentive Agreements (18 contracts)
- Compensation Agreements (1)
- Consulting Agreements (5)
- Employment Agreements (15)
- Severance Agreements (2)
- Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on August 8, 2024)
- Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on May 9, 2024)
- Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on November 7, 2023)
- Form of Deferred Stock Unit Notice and Deferred Stock Unit Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on August 4, 2022)
- Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on August 4, 2022)
- Form of Nonqualified Stock Option Award Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (June 2021 Retention Equity Awards) (Filed With SEC on August 5, 2021)
- Form of Stock Unit Notice and Stock Unit Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (June 2021 Retention Equity Awards) (Filed With SEC on August 5, 2021)
- Executive Employment Agreement, effective as of March 15, 2021, by and between Igor Bilinsky, Ph.D. and Iovance Biotherapeutics, Inc (Filed With SEC on May 6, 2021)
- Executive Employment Agreement, effective as of December 14, 2020, by and between Jean-Marc Bellemin and Iovance Biotherapeutics, Inc (Filed With SEC on February 25, 2021)
- Severance Agreement and General Release, effective July 8, 2020, between Iovance Biotherapeutics, Inc. and Timothy Morris (Filed With SEC on August 6, 2020)
- Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan, as amended (Filed With SEC on June 9, 2020)
- Form of Non-Qualified Stock Option Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on February 25, 2020)
- Form of Incentive Stock Option Agreement under the Iovance Biotherapeutics, Inc. 2018 Equity Incentive Plan (Filed With SEC on February 25, 2020)
- Form of Non-Qualified Stock Option Agreement under the Lion Biotechnologies, Inc. 2014 Equity Incentive Plan (Filed With SEC on February 25, 2020)
- Form of Incentive Stock Option Agreement under the Lion Biotechnologies, Inc. 2014 Equity Incentive Plan (Filed With SEC on February 25, 2020)
- Form of Non-Qualified Stock Option Agreement under the Genesis Biopharma Inc. 2011 Equity Incentive Plan (Filed With SEC on February 25, 2020)
- Form of Incentive Stock Option Agreement under the Genesis Biopharma Inc. 2011 Equity Incentive Plan (Filed With SEC on February 25, 2020)
- Executive Employment Agreement effective as of July 18, 2019, by and between Friedrich-Reinhard Graf Finck von Finckenstein, M.D (Filed With SEC on August 1, 2019)
- Form of NQSO Stock Option Agreement under the 2018 Equity Incentive Plan (Filed With SEC on August 7, 2018)
- Form of ISO Stock Option Agreement under the 2018 Equity Incentive Plan (Filed With SEC on August 7, 2018)
- Executive Employment Agreement, effective September 30, 2016, between Frederick G. Vogt and Lion Biotechnologies, Inc (Filed With SEC on March 12, 2018)
- Executive Employment Agreement, effective August 14, 2017, between Timothy E. Morris and Registrant (Filed With SEC on November 2, 2017)
- Consulting Agreement, dated September 14, 2017, between Iovance Biotherapeutics, Inc. and Iain Dukes, D. Phil (Filed With SEC on September 15, 2017)
- LION BIOTECHNOLOGIES, INC. 2017 CORPORATE GOALS—CASH BONUS PLAN (Filed With SEC on March 9, 2017)
- AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on March 9, 2017)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on October 3, 2016)
- SEVERANCE AGREEMENT AND GENERAL RELEASE (Filed With SEC on June 3, 2016)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on May 9, 2016)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on May 9, 2016)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on August 10, 2015)
- Executive Employment Agreement, dated August 21, 2014, by and among Lion Biotechnologies, Inc. and Dr. Elma Hawkins (Filed With SEC on August 26, 2014)
- REPLACEMENT EMPLOYMENT AGREEMENT (Filed With SEC on May 19, 2014)
- EXECUTIVE EMPLOYMENT AGREEMENT (Filed With SEC on January 7, 2014)
- CONSULTING AGREEMENT (Filed With SEC on March 30, 2012)
- CONSULTING AGREEMENT (Filed With SEC on March 30, 2012)
- AMENDMENT TO CONSULTING AGREEMENT DATEDFEBRUARY 15, 2011 BY AND BETWEEN EMMES GROUP CONSULTING LLC AND GENESIS BIOPHARMA, INC. (Filed With SEC on March 30, 2012)
- SECOND AMENDMENT TO CONSULTING AGREEMENTDATED FEBRUARY 15, 2011 BY AND BETWEEN EMMES GROUP CONSULTING LLC AND GENESIS BIOPHARMA, INC. (Filed With SEC on March 30, 2012)
- GENESIS BIOPHARMA, INC. 2011 EQUITY INCENTIVE PLAN (Filed With SEC on October 20, 2011)
- EMPLOYMENT AGREEMENT (Filed With SEC on October 20, 2011)
- EMPLOYMENT AGREEMENT (Filed With SEC on October 20, 2011)
